Pan-Cancer Analysis of HSP90AB1 Prognosis and Immune Effects: A Potential Target for Survival and Immunotherapy

Liu S, Shao X, Geng R and Wang J

College of Veterinary Medicine, Northeast Agricultural University, Harbin, China School of Life Sciences, Northeast Agricultural University, Harbin, China College of Food, Northeast Agricultural University, Harbin, China College of Engineering, Northeast Agricultural University, Harbin, China

^*Correspondance to: Shichao Liua 

 PDF  Full Text Research Article | Open Access

Abstract:

Emerging evidence reveals an important role of Heat shock protein 90 kDAα, Class B, Member 1 (HSP90AB1) in cancer initiation, development, and progression, but no pan-cancer analysis of HSP90AB1 has been performed. In this study, the expression profile and prognostic significance of HSP90AB1, as well as the relationship between HSP90AB1 and clinicopathological parameters and immune cell infiltration were comprehensively studied by bioinformatics technology. HSP90AB1 is significantly up regulated in a variety of common cancers and is associated with prognosis. Cox regression analysis showed that HSP90AB1 had high expression of bladder unessential carcinoma, cholangiocarcinoma, lung adenocarcinoma in Overall Survival (OS), Disease-Specific Survival (DSS), and Progression-Free Interval (PFI) were associated. In most cancers, HSP90AB1 DNA methylation is reduced and inversely correlated with HSP90AB1 expression. Increased phosphorylation in HSP90AB1 has been complied with in some cancers. HSP90AB1 was substantially correlated with infiltrating cell and immune checkpoint gene levels. Our pan-cancer analysis provides a multifaceted understanding of the function of HSP90AB1 in tumorigenesis and metastasis in different cancers.

Keywords:

HSP90AB1; Pan-cancer analysis; Prognostic biomarker; Immune cell infiltration; Cancer immunotherapy

Cite the Article:

Liu S, Shao X, Geng R, Wang J. Pan-Cancer Analysis of HSP90AB1 Prognosis and Immune Effects: A Potential Target for Survival and Immunotherapy. Clin Oncol. 2024; 9:2115..